Joslin Institute for Technology Translation (JITT) and Glooko, Introduce Hypoglycemia Awareness Product Designed to Improve Hypoglycemia Self-Management for People with Diabetes

(Boston, Massachusetts and Palo Alto, California) June 11 , 2014 – Joslin Institute for Technology Translation (JITT) at Joslin Diabetes Center, the world’s preeminent institution in diabetes research and clinical care, and Glooko Inc., a mobile, cloud based diabetes management system announced the release of their jointly developed Joslin HypoMap™ powered by Glooko™. Joslin HypoMap, powered by Glooko, is designed to improve health outcomes and reduce costs for use by patients and providers to improve self-management of hypoglycemia (low blood glucose events) as part of their diabetes management program. The Joslin HypoMap will be launched at the American Diabetes Association’s 74th Scientific Sessions, occurring June 13-17, 2014 in San Francisco. Visit us at booth #2149-Joslin Diabetes Center or #2241-Glooko.

Joslin HypoMap powered by Glooko incorporates a data-driven method to identify individuals with diabetes who have hypoglycemia unawareness, a condition that puts patients at higher risk for dangerous hypoglycemia episodes which can result in serious injury, hospitalization and even death. After experiencing a hypoglycemic event, patients are prompted to record symptoms, perceived causes, and self-treatments in the Joslin HypoMap mobile app. The results are then presented in a standardized, informative set of reports that are available to the patient and the designated patient’s care team. Joslin HypoMap powered by Glooko can be an effective self-management tool providing teachable moments with caregivers when patients miss opportunities to identify, record the symptom and treat a hypoglycemic event. The reports can also graphically present identifiable cyclical patterns related to a patient’s lifestyle habits that may contribute to the development of hypoglycemia.

“Patients rarely have an accurate recollection of the factors leading up to a hypoglycemia episode that occurred months before, and the opportunity to identify underlying causes and, therefore, prevent recurrences is lost,” said Howard Wolpert, MD, Director of the Joslin Institute for Technology Translation. “For the first time, clinicians can have substantive discussions about specific hypoglycemic events using key contextual data such as symptoms, causes, and treatments recorded in real-time, and subsequently help patients to improve their diabetes self-management skills and prevent future episodes.”

According to a study by Gurkirpal Singh, MD, Stanford, which was presented at the 2013 ADA Scientific Sessions, hypoglycemia was seen in a s many as 269,000 US hospitalizations for both Type I and Type 2 patients on insulin. This amounted to nearly $13B in charges in 2009. Joslin HypoMap powered by Glooko aims to create awareness in patients around causes and symptoms that precede their severe hypoglycemic events to provide a future knowledge base to avert possible serious consequences.

“Our partnership with Joslin embodies the transformational capabilities of the Joslin Institute for Technology Translation. In engaging patients and their care team in hypoglycemia awareness through the Joslin HypoMap and our mobile platform, we will jointly contribute to needed advances in diabetes self-management tools” said Rick Altinger, CEO, Glooko. “ By combining Joslin HypoMap with Glooko’s meter-agnostic system, we can improve diabetes patient care while also lowering costs to the overall healthcare system.”

In January, Glooko announced its partnership with Joslin Diabetes Center, a global leader in diabetes care, research and education. The stated purpose of the agreement is to use the Joslin clinical expertise and jointly deploy with Glooko an advanced diabetes technology platform that will allow patients to capture glucose and contextual data to allow for improved self-management tools initially involving hypoglycemia awareness.

Glooko’s FDA 510(k) cleared diabetes management system is available to health systems and payers and is designed to be integrated into EHR’s and other health record systems.

Joslin Diabetes Center does not promote or endorse any product. Revenue and fees from the JITT will be invested in digital health to improve patient care.

About Joslin Institute for Technology Translation (JITT)

Joslin Institute for Technology Translation is focused on leveraging the potential of technology with the introduction of clinical solutions and digital health to improve the lives of people with diabetes. JITT pairs Josli n Diabetes Center’s clinical expertise with industry to enhance the development of new and clinically effective technologies and digital health tools; it is uniquely positioned to provide clinical insight for medical devices, technologies and strategies for cost-efficient solutions that improve diabetes care and outcomes.

About Joslin Diabetes Center

Joslin Diabetes Center, based in Boston, Massachusetts, is committed to advancing diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives a nd offers real progress in preventing and curing diabetes. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education, and care. Its mission is to prevent, treat and cure diabetes and the organization’s vision is a world free of diabetes and its complications. For more information, visit http://www.joslin.org .

About Glooko Inc. Glooko is an innovative Silicon Valley company that delivers a mobile and cloud based, diabetes & chronic disease management system designed to improve health outcomes for people with diabetes and reduce the costs associated with diabetes population management. Glooko’s analytics and care management system includes direct integration to all major glucose meters and other health devices to supply timely, verified patient data such as blood glucose, carbs, insulin, activity, blood pressure, and weight data. Glooko executes diabetes-centric analytics and supplies standardized reports, risk flags and insights to case managers and Providers via API’s and web-based tools.

Glooko was founded in 2010 by technologist Yogen Dalal, mobile app developer Sundeep Madra, and Ch amath Palihapitiya, then a Facebook senior executive. Endocrinologist Michael S. Greenfield, M.D., is chief medical officer. In addition to the founders, investors include Samsung Venture Investment Corporation, Social + Capital Partnership, Lifeforce Vent ures, Judy Estrin, and Dr. Russell Hirsch.

Media Contacts:

Vikram Singh
Glooko
650 -­ 720 -­ 5310
press@glooko.com

Jeff Bright
Joslin Diabetes Center
617 – 309 -­ 1957
jeff.bright@joslin.harvard.edu